[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619746":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":40,"locations":48,"responsibleParty":64,"collaborators":27,"id":67,"slug":27,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":27,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":27,"enrollmentInfo":75,"targetDuration":27,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":51,"whyStopped":27,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Emory University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Opioid-Sparing Regimen","EXPERIMENTAL","Participants receive a standardized multimodal non-opioid analgesic regimen throughout the perioperative period and are discharged with placebo tablets instead of a standard opioid prescription. All participants receive counseling from a Life Care Specialist and a limited supply of rescue hydromorphone for severe breakthrough pain.",[13,14],"Drug: Placebo","Other: Multimodal Non-Opioid Analgesia",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard Opioid Prescription","ACTIVE_COMPARATOR","Participants receive the same standardized multimodal non-opioid analgesic regimen and Life Care Specialist counseling as the experimental group, but are discharged with a standard opioid prescription.",[20,14],"Drug: Oxycodone 5 mg",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Placebo","* 28 tablets identical in appearance to 5-mg oxycodone\n* Taken 1-2 tablets every 4 hours as needed for moderate to severe pain\n* Dispensed by Investigational Drug Services\n* Used in combination with standardized multimodal analgesia",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Oxycodone 5 mg","* 28 tablets of 5-mg oxycodone\n* Taken 1-2 tablets every 4 hours as needed for moderate to severe pain\n* Represents standard postoperative prescribing practi",[16],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Multimodal Non-Opioid Analgesia","Multimodal Non-Opioid Analgesia (Standardized Regimen)\n\nIncludes:\n\n* Acetaminophen\n* Meloxicam\n* Methylprednisolone taper\n* Spinal anesthesia\n* Periarticular local anesthetic injection\n* Postoperative scheduled acetaminophen and NSAIDs\n* Counseling by Life Care Specialist\n* Two 2-mg hydromorphone tablets for rescue only",[9,16],[37],{"name":38,"affiliation":5,"role":39},"Ajay Premkumar, MD","PRINCIPAL_INVESTIGATOR",[41,45],{"name":38,"role":42,"phone":43,"phoneExt":27,"email":44},"CONTACT","404-778-3350","ajay.premkumar@emory.edu",{"name":46,"role":42,"phone":27,"phoneExt":27,"email":47},"Darrell Favors","darrell.favors@emory.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Emory University Orthopedics and Spine Hospital","RECRUITING","Atlanta","Georgia","30329","United States",{"type":57,"coordinates":58},"Point",[59,60],-84.38798,33.749,{"lat":60,"lon":59},[63],{"name":38,"role":42,"phone":43,"phoneExt":27,"email":44},{"type":39,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Ajay Premkumar","Assistant Professor","100619746",false,"NCT07348627","Opioid-Sparing Joint Replacement","Opioid-Sparing Joint Replacement - Single Site Randomized Control Trial","Inclusion Criteria:\n\n* Diagnosis of hip osteoarthritis requiring primary arthroplasty\n* Scheduled to undergo anterior total hip arthroplasty (THA)\n* Able to comply with study procedures and follow-up visits\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Concurrent significant injuries to other bones or organs\n* Local infection at or near the surgical site\n* Preoperative opioid use within 4 weeks prior to surgery\n* History of severe heart disease (NYHA Class II or higher), renal failure, or liver dysfunction\n* Chronic liver disease\n* Neurological or psychiatric conditions that may influence pain perception\n* Pregnancy\n* History of alcohol or medication abuse\n* Inability to take NSAIDs\n* Use of postoperative DVT prophylaxis other than aspirin 81 mg twice daily\n* Diabetes mellitus with HbA1c \\> 8.0%\n* Diagnosis of chronic pain syndrome or fibromyalgia\n* Pain Catastrophizing Scale (PCS) score \\> 29\n* Any condition that, in the investigator's judgment, may interfere with adherence to study procedures or follow-up","ALL","18 Years",{"count":76,"type":77},120,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","The goal of this clinical trial is to evaluate whether an opioid-sparing postoperative pain regimen can reduce opioid consumption and maintain effective pain control in adults undergoing anterior total hip arthroplasty for osteoarthritis.\n\nThe main questions it aims to answer are:\n\n* Does an opioid-limited regimen result in lower postoperative opioid use compared with a standard opioid prescription?\n* Does the opioid-limited regimen provide comparable or improved postoperative pain control and patient satisfaction?",[83,84],"Pain Management","Opioid Consumption",[86,87,88,89],"Total hip arthroplasty","Numeric Rating Scale for pain","Visual Analog Scale for nausea","Life Care specialist","2026-04-14",{"date":92,"type":93},"2026-04-17","ACTUAL",{"date":95,"type":93},"2026-03-19",{"date":97,"type":77},"2028-08",{"name":5,"class":6},1]